81 related articles for article (PubMed ID: 21620801)
1. Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.
Ueda Y; Mori K; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2011 Jun; 409(4):663-8. PubMed ID: 21620801
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
[TBL] [Abstract][Full Text] [Related]
3. Efficient replication systems for hepatitis C virus using a new human hepatoma cell line.
Kato N; Mori K; Abe K; Dansako H; Kuroki M; Ariumi Y; Wakita T; Ikeda M
Virus Res; 2009 Dec; 146(1-2):41-50. PubMed ID: 19720094
[TBL] [Abstract][Full Text] [Related]
4. Anti-HCV activity of the Chinese medicinal fungus Cordyceps militaris.
Ueda Y; Mori K; Satoh S; Dansako H; Ikeda M; Kato N
Biochem Biophys Res Commun; 2014 May; 447(2):341-5. PubMed ID: 24726408
[TBL] [Abstract][Full Text] [Related]
5. A new living cell-based assay system for monitoring genome-length hepatitis C virus RNA replication.
Dansako H; Ikeda M; Abe K; Mori K; Takemoto K; Ariumi Y; Kato N
Virus Res; 2008 Oct; 137(1):72-9. PubMed ID: 18602954
[TBL] [Abstract][Full Text] [Related]
6. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
[TBL] [Abstract][Full Text] [Related]
7. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
8. Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.
Mori K; Ueda Y; Ariumi Y; Dansako H; Ikeda M; Kato N
Virus Genes; 2012 Jun; 44(3):374-81. PubMed ID: 22252251
[TBL] [Abstract][Full Text] [Related]
9. New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.
Ueda Y; Takeda M; Mori K; Dansako H; Wakita T; Kim HS; Sato A; Wataya Y; Ikeda M; Kato N
PLoS One; 2013; 8(8):e72519. PubMed ID: 24023620
[TBL] [Abstract][Full Text] [Related]
10. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
[TBL] [Abstract][Full Text] [Related]
12. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.
Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE
Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631
[TBL] [Abstract][Full Text] [Related]
13. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
[TBL] [Abstract][Full Text] [Related]
14. [Replication of hepatitis C virus genome].
Kato N
Uirusu; 2008 Dec; 58(2):191-8. PubMed ID: 19374197
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs.
Matsuno K; Ueda Y; Fukuda M; Onoda K; Waki M; Ikeda M; Kato N; Miyachi H
Bioorg Med Chem Lett; 2014 Sep; 24(17):4276-80. PubMed ID: 25086684
[TBL] [Abstract][Full Text] [Related]
16. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
Bourne N; Pyles RB; Yi M; Veselenak RL; Davis MM; Lemon SM
Antiviral Res; 2005 Aug; 67(2):76-82. PubMed ID: 15927278
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
Yano M; Ikeda M; Abe K; Dansako H; Ohkoshi S; Aoyagi Y; Kato N
Antimicrob Agents Chemother; 2007 Jun; 51(6):2016-27. PubMed ID: 17420205
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
[TBL] [Abstract][Full Text] [Related]
19. A cell-based bicistronic lentiviral reporter system for identification of inhibitors of the hepatitis C virus internal ribosome entry site.
Lourenço S; Boni S; Furling D; Cosset FL; Cahour A
J Virol Methods; 2009 Jun; 158(1-2):152-9. PubMed ID: 19428584
[TBL] [Abstract][Full Text] [Related]
20. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
